Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ISIS 304801-CS7 The APPROACH Open Label Study Volanesorsen (ISIS 304801) An Open-Label Study of Volanesorsen Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)

NCT02658175 is registered in ClinicalTrials.gov with Akcea Therapeutics as lead sponsor.

NCT NCT02658175
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02658175 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ISIS 304801-CS7 The APPROACH Open Label Study Volanesorsen (ISIS 304801) An Open-Label Study of Volanesorsen Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)
Lead sponsor
Akcea Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
December 23, 2015
Completion date
January 15, 2020
Enrollment
68 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

familial chylomicronemia syndrome, hyperlipoproteinemia type 1, lipoprotein lipase deficiency